Graphene Investments SAS Raises Holdings in Jazz Pharmaceuticals PLC $JAZZ

Graphene Investments SAS raised its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 30.1% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,800 shares of the specialty pharmaceutical company’s stock after purchasing an additional 6,200 shares during the quarter. Graphene Investments SAS’s holdings in Jazz Pharmaceuticals were worth $2,844,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of JAZZ. Hurley Capital LLC purchased a new stake in Jazz Pharmaceuticals in the 1st quarter valued at about $25,000. Picton Mahoney Asset Management increased its position in shares of Jazz Pharmaceuticals by 2,445.5% during the first quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company’s stock valued at $34,000 after acquiring an additional 269 shares during the last quarter. SVB Wealth LLC acquired a new stake in shares of Jazz Pharmaceuticals during the first quarter valued at about $36,000. Hantz Financial Services Inc. raised its stake in shares of Jazz Pharmaceuticals by 471.4% in the 2nd quarter. Hantz Financial Services Inc. now owns 360 shares of the specialty pharmaceutical company’s stock valued at $38,000 after acquiring an additional 297 shares during the period. Finally, Geneos Wealth Management Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 137 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Trading Down 0.4%

NASDAQ:JAZZ opened at $137.22 on Thursday. The company has a market capitalization of $8.32 billion, a PE ratio of -20.39, a P/E/G ratio of 8.49 and a beta of 0.29. Jazz Pharmaceuticals PLC has a 52-week low of $95.49 and a 52-week high of $148.06. The stock’s 50 day moving average price is $132.98 and its 200 day moving average price is $118.98. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The firm had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. Jazz Pharmaceuticals’s revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the company posted $5.30 earnings per share. On average, research analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total value of $771,720.00. Following the transaction, the director directly owned 429,973 shares in the company, valued at approximately $55,303,127.26. The trade was a 1.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last quarter, insiders have sold 11,500 shares of company stock worth $1,525,280. Company insiders own 4.30% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on JAZZ. Truist Financial increased their target price on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a “buy” rating in a research note on Thursday, August 28th. Wells Fargo & Company set a $170.00 price objective on Jazz Pharmaceuticals in a research report on Wednesday, October 22nd. Morgan Stanley set a $183.00 target price on shares of Jazz Pharmaceuticals in a report on Friday, October 24th. The Goldman Sachs Group lifted their price target on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a “buy” rating in a research note on Friday, August 29th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Jazz Pharmaceuticals in a research report on Wednesday, October 8th. Fourteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $179.33.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.